This interim analysis published in the Journal of the American Society Of Nephrology (JASN) and presented at the latest ASN Kidney Week, reports early results from the first clinical study in Asia testing ketogenic metabolic therapy, using a ketogenic diet supported by beta-hydroxybutyrate and alkaline citrate (KetoCitra®), in adults with ADPKD who had never received tolvaptan.

After three months, patients following the ketogenic program showed significantly greater weight loss and, notably, a 5% reduction in total kidney volume, while the control group experienced an 8% increase.

Kidney function (eGFR) remained stable in the intervention group, and no participants discontinued the diet, indicating good tolerability.

These early findings suggest that ketogenic metabolic therapy may be beneficial in slowing structural kidney changes in ADPKD.

Why is this important?ADPKD lacks many effective therapies, and early metabolic studies have shown that cyst growth is tightly linked to energy dysregulation in kidney cells.

This clinical evidence supports the idea that targeting metabolism, specifically through nutritional ketosis, can directly influence cyst expansion, offering a promising, non-pharmacologic therapeutic option.

The stability of eGFR, reduction in kidney volume, and high tolerability all strengthen the case for ketogenic interventions as an emerging strategy in ADPKD management.

Read Original Article Here-->